Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to 48.59%.

  • United Therapeutics' EBIT Margin rose 27800.0% to 48.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.63%, marking a year-over-year increase of 29200.0%. This contributed to the annual value of 47.86% for FY2024, which is 30500.0% down from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' EBIT Margin is 48.59%, which was up 27800.0% from 45.64% recorded in Q2 2025.
  • United Therapeutics' 5-year EBIT Margin high stood at 26010.0% for Q4 2023, and its period low was 4527.85% during Q4 2024.
  • For the 5-year period, United Therapeutics' EBIT Margin averaged around 1171.43%, with its median value being 48.59% (2025).
  • As far as peak fluctuations go, United Therapeutics' EBIT Margin skyrocketed by 259742700bps in 2023, and later crashed by -305378500bps in 2024.
  • Quarter analysis of 5 years shows United Therapeutics' EBIT Margin stood at 40.9% in 2021, then fell by -13bps to 35.73% in 2022, then skyrocketed by 72701bps to 26010.0% in 2023, then crashed by -117bps to 4527.85% in 2024, then soared by 101bps to 48.59% in 2025.
  • Its last three reported values are 48.59% in Q3 2025, 45.64% for Q2 2025, and 48.19% during Q1 2025.